摘要
目的观察NA方案(长春瑞滨联合表柔比星)和NP方案(长春瑞滨联合顺铂)治疗晚期乳腺癌的疗效及毒副反应。方法根据患者既往化疗史及病理,选取晚期或术后复发、转移的Ⅳ期女性乳腺癌患者53例,采用随机数字法进行分组,其中28例患者选用NA方案(长春瑞滨联合表柔比星),25例患者选用NP方案(长春瑞滨联合顺铂)化疗,每3-4周为1个周期。对两种化疗方案的有效率、疾病控制率和毒副反应率的比较采用χ2检验和四格表确切概率法,中位生存期估计用乘积极限法,生存率曲线比较用Log-rank检验。结果 NA方案有效率明显高于NP方案(60.7%vs32.0%,P<0.05);NA方案的疾病控制率高于NP方案(92.9%vs68.0%,P<0.05)。两方案间生存期及生存率相比,差异没有统计学意义(P>0.05)。两方案的毒副反应均以骨髓抑制和胃肠道反应为主。结论 NA方案治疗晚期乳腺癌的疗效优于NP方案,选择NA方案作为晚期乳腺癌患者的有效治疗措施是比较适合的。
Objective To observe the effect and toxicity of NA(NVB+EADM) and NP(NVB+DDP) regimens for advanced breast cancer. Methods According to the history of previous chemotherapy and pathology,53 patients with advanced or recurrent metastasis(stage Ⅳ) of breast cancer were selected and randomized into 2 groups.Twenty-eight patients were treated with vinorelbine(NVB,25 mg/m2 at day 1,8) plus epirubicin(EADM,60 mg/m2 at day 2,9) in the NA regimen every 3-4 weeks,and 25 patients were treated with vinorelbine(NVB,25 mg/m2 at day 1,8) plus cisplatin(DDP,40 mg/m2 at day 1-3) in the NP regimen every 3-4 weeks.The overall response rate,disease control rate and the toxicity between two regimens were analyzed using Chi-square test and Fisher's exact test.The median survival was estimated using the product-limit estimate.The survival curves were compared with Log-rank test. Results The response rate of the NA regimen was significantly higher than that of the NP regimen(60.7% vs 32.0%,P0.05) .The disease control rate of the NA regimen was also higher than that of the NP regimen(92.9% vs 68.0%,P0.05) .There was no statistical difference in survival time and survival rates between the two regimens(P0.05) .The main toxicities in the two regimens were myelosuppression and gastrointestinal reaction. Conclusion The effect of NA regimen is superior to that of NP regimen,so NA regimen is appropriate and better to treat the advanced breast cancer.
出处
《山西医科大学学报》
CAS
2010年第12期1077-1079,共3页
Journal of Shanxi Medical University
关键词
晚期乳腺癌
长春瑞滨
表柔比星
顺铂
疗效
advanced breast cancer
vinorelbine
epirubicin
cisplatin
efficacy